Enhancing PD-L1 Degradation by ITCH during MAPK Inhibitor Therapy Suppresses Acquired Resistance

MAPK inhibitor (MAPKi) therapy in melanoma leads to the accumulation of tumor-surface PD-L1/L2, which may evade antitumor immunity and accelerate acquired resistance. Here, we discover that the E3 ligase ITCH binds, ubiquitinates, and downregulates tumor-surface PD-L1/L2 in MAPKi-treated human melan...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Zhentao, Wang, Yan, Liu, Sixue, Deng, Weixian, Lomeli, Shirley H., Moriceau, Gatien, Wohlschlegel, James, Piva, Marco, Lo, Roger S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357203/
https://www.ncbi.nlm.nih.gov/pubmed/35638972
http://dx.doi.org/10.1158/2159-8290.CD-21-1463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357203/
https://www.ncbi.nlm.nih.gov/pubmed/35638972
http://dx.doi.org/10.1158/2159-8290.CD-21-1463

Ejemplares similares